Disease Uncovered

Next-generation sequencing can be used to detect and diagnose minimal residual disease in patients with T-lineage acute lymphoblastic leukemia/lymphoma, report researchers led by Harlan Robins at the Fred Hutchinson Cancer Research Center. Using 43 matched pairs of T-ALL samples, the researchers compared the abilities of next-gen sequencing and multiparametric flow cytometry to detect minimal residual disease and found that sequencing was equivalent to or better than flow cytometry, as they report in Science Translational Medicine. "Our research indicates that HTS [high-throughput sequencing] offers many advantages over flow cytometry," Robins says in a statement. "Since HTS can detect any pre-identified clone and is performed in a centralized lab, it consistently generates reproducible and reliable results regardless of cancer type, using the same process for disease detection and tracking. Furthermore, HTS is highly automated, cost-effective and objective, whereas flow cytometry is more time consuming, relies on the skill of the operator and is therefore subject to human error."

The press release adds that the Hutchinson Center has patents pending on some of the technologies used in this study.